Trial · NCT07914660
Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)
NCT07914660, Phase 2, Not yet recruiting, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a). Trials, record NCT07914660. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07914660
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)
- NCT number
- NCT07914660
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 192 participants, estimated
- Lead sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
- Conditions
- Hyperlipoproteinemia (a)
- Interventions
- YKYY032 group, YKYY032 Placebo group
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The percentage change from baseline in time average Lp(a) over Days 60-180. | Baseline, Days 60 - 180 | |
| Secondary | The proportion of participants achieving Lp(a) < 125 nmol/L and < 75 nmol/L at Days 60, 180, 240, 360 and 540. | Days 60, 180, 240, 360 and 540 | |
| Secondary | The percentage change of Lp(a) from the baseline at Days 60, 180, 240, 360 and 540. | Baseline, Days 60, 180, 240, 360 and 540 | |
| Secondary | The absolute value of the change of Lp(a) from the baseline at Days 60, 180, 240, 360 and 540. | Baseline, Days 60, 180, 240, 360 and 540 | |
| Secondary | The percentage change of LDL-C from the baseline at Days 60, 180, 240, 360 and 540. | Baseline, Days 60, 180, 240, 360 and 540 | |
| Secondary | The percentage change of ApoB from the baseline at Days 60, 180, 240, 360 and 540. | Baseline, Days 60, 180, 240, 360 and 540 | |
| Secondary | The percentage change from baseline in other lipid parameters, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C) at Days 60, 180, 240, 360 and 540. | Baseline, Days 60, 180, 240, 360 and 540 | |
| Secondary | Percent change in High-sensitivity C-reactive Protein (hsCRP) from baseline. | Baseline, Days 60, 180, 240, 360 and 540 | |
| Secondary | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of YKYY032 | Day 1: pre-dose, post-dose 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 2), 46-50 hours (Day 3); Day 180: 1-3 hours, 3-6 hours, 7-9 hours, 22-26 hours (Day 181), 46-50 hours (Day 182) post-dose | |
| Secondary | The incidence and severity of adverse events (TEAE); Vital signs, physical examination results, laboratory test results, 12-lead electrocardiogram (ECG), etc. | During the clinical trial period, up to Day 540. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07914660
GET https://conductscience.org/api/trials/v1/NCT07914660/registered